$1.85
3.35%
Nasdaq, Apr 21, 07:52 pm CET
ISIN
IL0011429839
Symbol
ENTX
Sector
Industry

Entera Bio Ltd. Stock price

$1.79
-0.16 8.21% 1M
-0.04 2.19% 6M
-0.33 15.57% YTD
-0.43 19.37% 1Y
-0.98 35.38% 3Y
-0.19 9.60% 5Y
-4.49 71.50% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.03 1.70%
ISIN
IL0011429839
Symbol
ENTX
Sector
Industry

Key metrics

Market capitalization $81.30m
Enterprise Value $72.91m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 405.06
P/S ratio (TTM) P/S ratio 451.67
P/B ratio (TTM) P/B ratio 8.60
Revenue (TTM) Revenue $180.00k
EBIT (operating result TTM) EBIT $-9.59m
Free Cash Flow (TTM) Free Cash Flow $-6.82m
Cash position $8.66m
EPS (TTM) EPS $-0.25
Short interest 0.19%
Show more

Is Entera Bio Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Entera Bio Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Entera Bio Ltd.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Entera Bio Ltd.:

Buy
100%

Financial data from Entera Bio Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.18 0.18
-
100%
- Direct Costs 0.19 0.19
217% 217%
106%
- -
-
-
- Selling and Administrative Expenses 5.05 5.05
16% 16%
2,806%
- Research and Development Expense 4.49 4.49
1% 1%
2,494%
-9.54 -9.54
7% 7%
-5,300%
- Depreciation and Amortization 0.05 0.05
17% 17%
28%
EBIT (Operating Income) EBIT -9.59 -9.59
7% 7%
-5,325%
Net Profit -9.54 -9.54
7% 7%
-5,300%

In millions USD.

Don't miss a Thing! We will send you all news about Entera Bio Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Entera Bio Ltd. Stock News

Neutral
GlobeNewsWire
24 days ago
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.
Neutral
GlobeNewsWire
about one month ago
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, met...
Neutral
GlobeNewsWire
about 2 months ago
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the Company will participate at the following conferences.
More Entera Bio Ltd. News

Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Miranda Toledano
Employees 20
Founded 2009
Website www.enterabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today